Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose safety, PK, PD, and food-effect study of LTI-291 in healthy volunteers
NL-OMON44238Phase 1Active, not recruiting
- Sponsor
- Lysosomal Therapeutics
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of pariceract in Parkinson's disease (PD) (2 arms), sponsored by Lysosomal Therapeutics. Primary endpoints: Safety and tolerability endpoints, Pharmacokinetic endpoints and 1 more. Started Aug 2017; status: active, not recruiting.
02
Drugs
pariceract
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NL-OMON44238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44238.